Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6230616 | 0.92 | NQO2 (0.41) | PLA2G2ANQO2POLBKMT2AKDM4E | |
| SCHEMBL6231676 | 0.90 | NQO2 (0.40) | PLA2G2ANQO2POLBKMT2AKDM4E | |
| SCHEMBL8569839 | 0.86 | AKR1C4 (0.42) | MEN1KMT2AAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL9055766 | 0.81 | NQO2 (0.39) | PLA2G2ANQO2POLBKMT2AKDM4E | |
| SCHEMBL9055771 | 0.81 | NQO2 (0.39) | PLA2G2ANQO2POLBKMT2AKDM4E | |
| SCHEMBL8572170 | 0.80 | ALDH1A1 (0.41) | PLA2G2ANQO2POLBMEN1KMT2A | |
| SCHEMBL8574414 | 0.80 | ALDH1A1 (0.41) | PLA2G2ANQO2MEN1KMT2AKDM4E | |
| SCHEMBL5755105 | 0.79 | EGFR (0.48) | PLA2G2APOLBMEN1KMT2AKDM4E | |
| SCHEMBL8573362 | 0.76 | GABRP (0.46) | NQO2KDM4E | |
| SCHEMBL8569654 | 0.76 | POLB (0.45) | POLBMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1004582-B1 | Pyridazino quinoline compounds | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| EP-0790996-B1 | PYRIDAZINOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-27 | — | — | EP | disclosed |
| US-6232313-B1 | TREATING STROKE OR EPILEPTIC CONVULSIONS ASSOCIATED WITH EXCESSIVE CALCIUM INFLUX IN THE BRAIN CAUSED BY EXCITATORY AMINO ACIDS | ZENECA LIMITED (GB) | 2001-05-15 | — | — | US | disclosed |
| US-6214826-B1 | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 2001-04-10 | — | — | US | disclosed |
| EP-0724583-B1 | PYRIDAZINO QUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-13 | — | — | EP | disclosed |
| EP-1004582-A2 | Pyridazino quinoline compounds | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| US-5744471-A | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 1998-04-28 | — | — | US | disclosed |
| EP-0790996-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| EP-0724583-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996015127-A1 | PYRIDAZINOQUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| WO-1995011244-A1 | PYRIDAZINO QUINOLINE COMPOUNDS | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |